Geron Corporation (GERN)
NasdaqGS · USD · Healthcare · Biotechnology
$1.15 (+2.68%) as of
Key statistics
- Market cap
- 738.84M
- Forward P/E
- 28.75
- EPS (TTM)
- -0.1100
- Dividend yield
- 0.00%
- 52-week range
- 1.0400 – 2.0100
- Beta
- 0.61
- Revenue (TTM)
- 204.56M
- Profit margin
- -33.05%
- Analyst target
- $4.25
- Volume
- 11.09M
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Foster City, CA, United States
- Employees
- 258
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.